About Clementia Pharmaceuticals (NASDAQ:CMTA)
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. Its lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. The company is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-2.22
Forward P/E Ratio-13.26
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$4.47 per share
Price / Book3.94
EPS (Most Recent Fiscal Year)($7.93)
Return on EquityN/A
Return on Assets-117.13%
Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions
What is Clementia Pharmaceuticals' stock symbol?
Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."
How were Clementia Pharmaceuticals' earnings last quarter?
Clementia Pharmaceuticals (NASDAQ:CMTA) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.03. View Clementia Pharmaceuticals' Earnings History.
When is Clementia Pharmaceuticals' next earnings date?
What price target have analysts set for CMTA?
5 brokerages have issued 12-month target prices for Clementia Pharmaceuticals' stock. Their predictions range from $23.00 to $32.00. On average, they expect Clementia Pharmaceuticals' stock price to reach $26.60 in the next twelve months. View Analyst Ratings for Clementia Pharmaceuticals.
Who are some of Clementia Pharmaceuticals' key competitors?
Some companies that are related to Clementia Pharmaceuticals include Dynavax Technologies (DVAX), Epizyme (EPZM), TG Therapeutics (TGTX), Intra-Cellular Therapies (ITCI), Retrophin (RTRX), Athenex (ATNX), Zai Lab (ZLAB), CytomX Therapeutics (CTMX), Uniqure (QURE), MacroGenics (MGNX), Access Pharmaceuticals (ABEO), Biohaven Pharmaceutical (BHVN), Assembly Biosciences (ASMB), Flexion Therapeutics (FLXN), Alder BioPharmaceuticals (ALDR), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX) and Inflarx (IFRX).
Who are Clementia Pharmaceuticals' key executives?
Clementia Pharmaceuticals' management team includes the folowing people:
- Dr. Clarissa Desjardins Ph.D., Pres, CEO & Director
- Mr. Michael Singer CGA, CFO & Corp. Sec.
- Dr. Donna Roy Grogan M.D., Chief Medical Officer
- Mr. Jeffery Packman, Chief Devel. Officer
- Mr. Eric Grinstead, Chief Commercial Officer
When did Clementia Pharmaceuticals IPO?
(CMTA) raised $101 million in an initial public offering on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at $13.00-$15.00 per share. Morgan Stanley and Leerink Partners acted as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.
Has Clementia Pharmaceuticals been receiving favorable news coverage?
Press coverage about CMTA stock has trended somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Clementia Pharmaceuticals earned a news impact score of 0.17 on Accern's scale. They also assigned news headlines about the company an impact score of 46.23 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Clementia Pharmaceuticals' major shareholders?
How do I buy shares of Clementia Pharmaceuticals?
Shares of CMTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clementia Pharmaceuticals' stock price today?
One share of CMTA stock can currently be purchased for approximately $17.63.
How big of a company is Clementia Pharmaceuticals?
Clementia Pharmaceuticals has a market capitalization of $583.61 million. The company earns $-115,450,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe.
How can I contact Clementia Pharmaceuticals?
Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected]
MarketBeat Community Rating for Clementia Pharmaceuticals (CMTA)MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CMTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Clementia Pharmaceuticals (NASDAQ:CMTA) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Clementia Pharmaceuticals (NASDAQ CMTA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 68.04%
Clementia Pharmaceuticals (NASDAQ CMTA) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Clementia Pharmaceuticals (NASDAQ CMTA) News Headlines
Clementia Pharmaceuticals (NASDAQ:CMTA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Clementia Pharmaceuticals (NASDAQ:CMTA) Income Statement, Balance Sheet and Cash Flow Statement
Clementia Pharmaceuticals (NASDAQ CMTA) Stock Chart for Sunday, April, 22, 2018